Business, energy, technology, markets and global industry news from Business News Today

Yeztugo

PharmaDeviceNews Yeztugo
Representative image of an HIV prevention consultation, as Gilead Sciences’ once weekly oral Yeztugo filing puts long acting PrEP and future FDA review in focus.
Pharma & Biotech

Gilead’s once weekly Yeztugo bid could challenge the old daily pill versus injection divide

Read how Gilead’s once weekly oral Yeztugo filing could reshape HIV prevention, PrEP adherence and long acting therapy competition.

Read More
Representative image: Gilead Sciences’ HIV drug growth helped lift its Q1 performance, highlighting how Biktarvy, Descovy and long-acting prevention therapies remain central to the company’s biopharma growth story.
Pharma & Biotech

Gilead’s Q1 shows HIV momentum remains powerful, but diversification is still unfinished

Gilead’s HIV engine is roaring again. But acquisition costs and oncology pressure leave investors asking how durable the reset really is.

Read More